The analysis of the relationship between transferrin receptor 1 (TfR1) and clinical, morphological and immunophenotypic characteristics of breast cancer: retrospective cohort study
Open Access
- 25 November 2022
- journal article
- research article
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 24 (3) , 355-360
Abstract
Background. Transferrin receptor 1 (TfR1) expression has been identified in a number of malignant tumors. It is noted that its overexpression gives growth advantages to cancer cells. Estimation of transferrin receptor expression in breast cancer (BC) might be an important component in disease prognosis, choice of treatment, also might be an attractive target for targeted therapy. Aim. To evaluate the expression of TfR1 by BC cells and to study its relationship with the clinical, morphological and immunophenotypic characteristics of the tumor. Materials and methods. This study included 82 patients with BC who received treatment at the Blokhin National Medical Research Center of Oncology (Moscow). The expression of TfR1 on primary tumor cells was studied, the relationship of TfR1 with clinical, morphological and immunophenotypic characteristics of BC was analyzed. Immunophenotyping of the primary tumor was performed by the immunohistochemical method (immunofluorescent staining) on cryostat sections. Antibodies to CD71, CD95, CD54, CD29, MUC1, Pgp170 were used. The reaction was evaluated using a luminescent microscope (AXIOSKOP, Germany). The study was dominated by patients with stage IIB 54% and IIIB 21%. Infiltrative ductal BC was diagnosed in 67% (n=55) of patients, infiltrative-lobular in 22% (n=18) of cases, other types in 11.0% (n=9). Results. BC cells expressed TfR1 in most cases (64.4%; n=61). A combination of TfR1 monomorphic expression with MUC1 monomorphic expression (74.4%; n=47) was noted. CD29 is presented both mosaic (38.7%) and monomorphic (51.6%). The Pgp170 antigen was monomorphically observed in 27.5% of cases. As the proportion of TfR+ cells increased, the expression frequency of the adhesion molecule CD54 increased from 10.5 to 33.3%, a positive correlation was established (r=0.293; p=0.008). In the group with TfR1 monomorphic expression, the frequency of tumors expressing the CD95 apoptosis molecule decreased: 25.0% vs 13% (p=0.042). Conclusion. BC cells overexpress TfR1. TfR1 expression is associated with tumor immunophenotype.Keywords
This publication has 24 references indexed in Scilit:
- TfR1 interacts with the IKK complex and is involved in IKK–NF-κB signallingBiochemical Journal, 2012
- Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cellsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2012
- The pentose phosphate pathway: An antioxidant defense and a crossroad in tumor cell fateFree Radical Biology and Medicine, 2012
- How the binding of human transferrin primes the transferrin receptor potentiating iron release at endosomal pHProceedings of the National Academy of Sciences, 2011
- Absence of CD71 Transferrin Receptor Characterizes Human Gastric Adenosquamous Carcinoma Stem CellsAnnals of Surgical Oncology, 2011
- Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifenBreast Cancer Research and Treatment, 2009
- Potential identity of multi-potential cancer stem-like subpopulation after radiation of cultured brain gliomaBMC Neuroscience, 2008
- The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancerClinical Immunology, 2006
- Ferritin Heavy Chain Upregulation by NF-κB Inhibits TNFα-Induced Apoptosis by Suppressing Reactive Oxygen SpeciesCell, 2004
- Structure of the Human Transferrin Receptor-Transferrin ComplexCell, 2004